Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1997;29:115-122

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connell, D. P.
Right arrow Articles by Carey, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connell, D. P.
Right arrow Articles by Carey, R. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*LITHIUM COMPOUNDS
*LITHIUM, ELEMENTAL
*SODIUM

(Hypertension. 1997;29:115.)
© 1997 American Heart Association, Inc.


Research Articles (Issue 1, Part 1)

Differential Human Renal Tubular Responses to Dopamine Type 1 Receptor Stimulation Are Determined by Blood Pressure Status

Damian P. O'Connell; N. Virginia Ragsdale; David G. Boyd; Robin A. Felder; Robert M. Carey

the Department of Pharmacology and Therapeutics, University College Cork (Ireland) (D.P.O'C.), and the Departments of Medicine and Pathology, University of Virginia Health Sciences Center, Charlottesville.

Correspondence to Dr Robert M. Carey, Box 395, University of Virginia Health Sciences Center, Charlottesville, VA 22908. E-mail rmc4c@virginia.edu.

We performed the present studies to determine whether a proximal renal tubular dopamine D1-like receptor defect exists in human essential hypertension. Twenty-four subjects were studied (13 normotensive and 11 hypertensive) in a randomized, double-blind, vehicle-controlled study using fenoldopam, a selective D1-like receptor agonist. Subjects were studied in sodium metabolic balance at 300 mEq/d, after which the salt sensitivity of their blood pressure was determined. Fenoldopam at peak doses of 0.1 to 0.2 µg/kg per minute decreased mean arterial pressure in hypertensive subjects but did not change mean pressure in normotensive subjects. Fenoldopam increased renal plasma flow to a greater extent in hypertensive than normotensive subjects. Fenoldopam increased both urinary and fractional sodium excretions in the hypertensive and normotensive groups. In normotensive but not hypertensive subjects, fenoldopam increased the fractional excretion of lithium and distal sodium delivery. In contrast, both distal fractional sodium reabsorption and sodium-potassium exchange fell significantly in hypertensive subjects. We conclude that human essential hypertension is associated with a reduction in the proximal tubular response to D1-like receptor stimulation compared with normotensive subjects. Hypertensive subjects appear to have a compensatory upregulation of renal vascular and distal tubular D1-like receptor function that offsets the proximal tubular defect, resulting in an enhanced natriuretic response to D1-like receptor stimulation.


Key Words: receptors, dopamine • blood pressure • kidney tubules, proximal • dopamine agonists




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
C. S. Wilcox and A. Pearlman
Chemistry and Antihypertensive Effects of Tempol and Other Nitroxides
Pharmacol. Rev., December 1, 2008; 60(4): 418 - 469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Zeng, I. Armando, Y. Luo, G. M. Eisner, R. A. Felder, and P. A. Jose
Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H551 - H569.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. J. Gildea, X. Wang, P. A. Jose, and R. A. Felder
Differential D1 and D5 Receptor Regulation and Degradation of the Angiotensin Type 1 Receptor
Hypertension, February 1, 2008; 51(2): 360 - 366.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Z. Wang, I. Armando, L. D. Asico, C. Escano, X. Wang, Q. Lu, R. A. Felder, C. G. Schnackenberg, D. R. Sibley, G. M. Eisner, et al.
The elevated blood pressure of human GRK4{gamma} A142V transgenic mice is not associated with increased ROS production
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2083 - H2092.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
H. Sanada, J. Yatabe, S. Midorikawa, S. Hashimoto, T. Watanabe, J. H. Moore, M. D. Ritchie, S. M. Williams, J. C. Pezzullo, M. Sasaki, et al.
Single-Nucleotide Polymorphisms for Diagnosis of Salt-Sensitive Hypertension
Clin. Chem., March 1, 2006; 52(3): 352 - 360.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
C. Zeng, H. Sanada, H. Watanabe, G. M. Eisner, R. A. Felder, and P. A. Jose
Functional genomics of the dopaminergic system in hypertension
Physiol Genomics, November 17, 2004; 19(3): 233 - 246.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Zeng, D. Wang, L. D. Asico, W. J. Welch, C. S. Wilcox, U. Hopfer, G. M. Eisner, R. A. Felder, and P. A. Jose
Aberrant D1 and D3 Dopamine Receptor Transregulation in Hypertension
Hypertension, March 1, 2004; 43(3): 654 - 660.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. W. Stone, P. A. McCullough, J. A. Tumlin, N. E. Lepor, H. Madyoon, P. Murray, A. Wang, A. A. Chu, G. L. Schaer, M. Stevens, et al.
Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy: A Randomized Controlled Trial
JAMA, November 5, 2003; 290(17): 2284 - 2291.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
T. Hussain and M. F. Lokhandwala
Renal Dopamine Receptors and Hypertension
Experimental Biology and Medicine, February 1, 2003; 228(2): 134 - 142.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. A. Felder, H. Sanada, J. Xu, P.-Y. Yu, Z. Wang, H. Watanabe, L. D. Asico, W. Wang, S. Zheng, I. Yamaguchi, et al.
G protein-coupled receptor kinase 4 gene variants in human essential hypertension
PNAS, March 19, 2002; 99(6): 3872 - 3877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. A. Ladines, C. Zeng, L. D. Asico, X. Sun, F. Pocchiari, C. Semeraro, J. Pisegna, S. Wank, I. Yamaguchi, G. M. Eisner, et al.
Impaired renal D1-like and D2-like dopamine receptor interaction in the spontaneously hypertensive rat
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1071 - R1078.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. M. Carey
Renal Dopamine System: Paracrine Regulator of Sodium Homeostasis and Blood Pressure
Hypertension, September 1, 2001; 38(3): 297 - 302.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Sato, M. Soma, T. Nakayama, and K. Kanmatsuse
Dopamine D1 Receptor Gene Polymorphism Is Associated With Essential Hypertension
Hypertension, August 1, 2000; 36(2): 183 - 186.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Sanada, P. A. Jose, D. Hazen-Martin, P.-Y. Yu, J. Xu, D. E. Bruns, J. Phipps, R. M. Carey, and R. A. Felder
Dopamine-1 Receptor Coupling Defect in Renal Proximal Tubule Cells in Hypertension
Hypertension, April 1, 1999; 33(4): 1036 - 1042.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Hussain and M. F. Lokhandwala
Renal Dopamine Receptor Function in Hypertension
Hypertension, August 1, 1998; 32(2): 187 - 197.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Ricci, E. Bronzetti, P. Mulatero, M. Schena, F. Veglio, and F. Amenta
Dopamine D3 Receptor in Peripheral Mononuclear Cells of Essential Hypertensives
Hypertension, December 1, 1997; 30(6): 1566 - 1571.
[Abstract] [Full Text]